Retatrutide

SAN ANTONIO — In patients with obesity, the novel triple receptor agonist retatrutide was associated with improvement in health-related quality of life vs. placebo, a speaker reported.

After decades of research, pharmacologic treatment of obesity gained significant traction with the launch of GLP-1 receptor agonists, and several potentially more potent drugs are currently in the pipeline, a speaker reported.

Bariatric surgery will continue to be a therapeutic option for obesity and early diabetes in the future and may be used in combination with newer medications, according to a speaker.

A slew of new medications currently in development may allow health care providers to go beyond glycemic management in the treatment of type 2 diabetes, according to a speaker.

Adults with obesity can lose 15% or more of their body weight with nutrient-stimulated hormone-based therapies, but reducing body weight is not the only goal providers should have when treating obesity, according to a speaker.

The development of incretin-based molecules has led to therapies that can induce greater reductions in HbA1c and body weight for people with type 2 diabetes and obesity than other classes of medication, according to a speaker

DALLAS — In this Healio video exclusive, Ania M. Jastreboff, MD, PhD, highlights several medications that may have a large impact on obesity care in the near future.

DALLAS — Weight loss with the triple-hormone agonist retatrutide varies by sex, age and baseline BMI, according to a speaker.

A new generation of obesity drugs is changing the treatment landscape for patients and providers, with options that can lead to weight loss unheard of just a few years ago.

SAN DIEGO — Adults with obesity who received the highest dose of a once-weekly injection of retatrutide lost an average of 24.2% of their body weight at 48 weeks compared with placebo, data from a phase 2 study show.